Risperidone Viatris

Country: Նոր Զելանդիա

language: անգլերեն

source: Medsafe (Medicines Safety Authority)

active_ingredient:

Risperidone 2mg

MAH:

Viatris Limited

INN:

Risperidone 2 mg

dosage:

2 mg

pharmaceutical_form:

Film coated tablet

composition:

Active: Risperidone 2mg Excipient: Colloidal silicon dioxide Lactose monohydrate Magnesium stearate Microcrystalline cellulose Opadry orange 03H53577 Sodium laurilsulfate Starch

prescription_type:

Prescription

manufactured_by:

Mylan Laboratories Limited

therapeutic_indication:

Indicated for the treatment of schizophrenia and other psychotic disorders. These include first episode pyschoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent. Risperidone also alleviates affective symptoms (such as depression, guilt feelings, anxiety) associated with schizophrenia. Risperidone also appears effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial response to treatment with this agent.

leaflet_short:

Package - Contents - Shelf Life: Blister pack, PVC/PE/PVdC and aluminium foil blister pack, packaged in a cardboard carton - 20 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, PVC/PE/PVdC and aluminium foil blister pack, packaged in a cardboard carton - 60 tablets - 36 months from date of manufacture stored at or below 25°C

authorization_date:

2013-10-23